Cory Renauer
Value, research analyst, biotech, small-cap

Anika Therapeutics: Profitable, Cheap And Overlooked

Looking over Anika Therapeutics (NASDAQ:ANIK) reminded me of one of my favorite Peter Lynch quotes: "When even the analysts are bored, it's time to start buying." According to the company's investor relations site, Anika is covered by three. During the Q1 2013 earnings call, only five analysts bothered tuning in. Let's see if this company is as boring as it seems.

Anika makes therapeutic products involved in tissue protection, healing and repair. Anika's products are based on a naturally occurring, biocompatible polymer, called hyaluronan, or hyaluronic acid (HA). The company uses its proprietary technologies to modify the HA molecule and tailor it for specific, therapeutic applications.

Fundamentally sound and growing

According to the company's latest 10-Q filing,...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details